<u>AMENDMENT</u>

Please cancel claim 10 and amend claim 1 as shown herein.

- 1. (Currently Amended) In a therapeutic composition comprising a BPI bactericidal/permeability-increasing protein product and a stabilizing polyoxypropylene-poloxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant.
- 2. (Original) The therapeutic composition of claim 1 further comprising EDTA.
- 3. (Original) The improved composition of claim 1 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.
- 4. (Original) The therapeutic composition of claim 3 further comprising EDTA.
 - 5. (Withdrawn)
 - 6. (Withdrawn)
 - 7. (Withdrawn)
 - 8. (Withdrawn)
- 9. (Original) A composition for inhibiting bacterial and fungal growth comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.
 - 10. (Cancelled)
- (Original) The composition of claim 9 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

- 12. (Withdrawn)
- 13. (Withdrawn)
- 14. (Withdrawn)